SCHEMBL4338412

SCHEMBL4338412

Cc1cc(=O)n(-c2nccc(C(F)(F)F)n2)[nH]1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB1 P08588 1/20 0.46
KDM5A P29375 1/20 0.45
KDM2B Q8NHM5 1/20 0.45
KDM4C Q9H3R0 1/20 0.45
ALDH1A1 P00352 7/20 0.41
MAPT P10636 6/20 0.41
KMT2A Q03164 5/20 0.41
ALPL P05186 1/20 0.40
KDM4E B2RXH2 6/20 0.40
HTR2C P28335 5/20 0.40
HTR2A P28223 4/20 0.40
HTR2B P41595 4/20 0.40
GAA P10253 2/20 0.40
HTT P42858 2/20 0.40
MEN1 O00255 2/20 0.40
ALKBH3 Q96Q83 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.38
LMNA P02545 1/20 0.38
RECQL P46063 1/20 0.38
TDP1 Q9NUW8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4338380 0.67 MAPT (0.63) ALDH1A1MAPTKMT2AALPLKDM4E
SCHEMBL30401634 0.67 ADRB1 (0.46) ADRB1KMT2AKDM4EHTR2CHTR2A
SCHEMBL8354208 0.65 ADRB1 (0.78) ADRB1ALDH1A1KMT2AKDM4EHTR2C
SCHEMBL15297136 0.65 ADRB1 (0.47) ADRB1ALDH1A1MAPTKMT2AKDM4E
SCHEMBL171691 0.64 ADRB1 (0.43) ADRB1KDM4EHTR2CHTR2AHTR2B
SCHEMBL9323005 0.64 KMT2A (0.54) KDM5AKDM2BKDM4CALDH1A1MAPT
SCHEMBL4746365 0.64 NOX4 (0.63) KDM5AKDM2BKDM4CALDH1A1MAPT
SCHEMBL4338425 0.64 ALKBH5 (0.64) ALDH1A1MAPTKMT2AKDM4EHTR2C
SCHEMBL28070992 0.63 ADRB1 (0.73) ADRB1ALDH1A1KMT2AKDM4EHTR2C
SCHEMBL7716577 0.63 KDM4E (0.63) ALDH1A1KMT2AKDM4EMEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130078213-A1 THROMBOPOIETIN MIMETICS GLAXOSMITHKLINE LLC 2013-03-28 US disclosed
EP-1889838-B1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORP (US) 2009-10-14 EP disclosed
EP-1889838-A1 Thrombopoietin mimetics SmithKline Beecham Corporation (US) 2008-02-20 EP disclosed
EP-1864981-A1 Thrombopoietin mimetics SmithKline Beecham Corporation (US) 2007-12-12 EP disclosed
US-20070129338-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION 2007-06-07 US disclosed
US-20040019190-A1 Thrombopoietin mimetics NOVARTIS AG (CH) 2004-01-29 US disclosed
EP-1294378-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2004-01-28 EP disclosed
EP-1294378-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-26 EP disclosed
WO-2001089457-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2001-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129338-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK ADRB1 1726/4885KDM5A 2479/4885KDM2B 1080/4885
US-20130078213-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK ADRB1 1726/4885KDM5A 2479/4885KDM2B 1080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.